SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

April 13, 2018: By Jon Swedien

Swiss Advanced Vision (SAV-IOL) is looking to raise $20 million to bring an active intraocular lens with real-time autofocus to market in the next five to 10 years, the company announced April 10.

The Swiss company said it is developing the R-TASC (Real-Time Autofocus Servo Control), an active lens with real-time autofocus and wireless connectivity.

The purpose of R-TASC is to fully restore the accommodative function normally provided by the crystalline lens of the eye, SAV-IOL said.

The R-TASC lens is based on an energy capture system and will focus on any object viewed by the patient in real-time, the company said. SAV-IOL said the platform will also incorporate augmented reality and other interactive or connected features.

The R-TASC will be fitted alongside a monofocal lens (for distance vision) or added on patients who already have a monofocal lens but want to restore their visual accommodation, SAV-IOL said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US Health Secretary Alex Azar Takes Aim at Rebates in US Senate Hearing

Beyeonics Surgical Raises $11.5 Million in Initial Funding Round

MeiraGTx Raises $75 Million in Initial Public Offering

GenSight to Pursue Approval for LHON Gene Therapy Candidate, Despite Phase III Setback

Optovue Receives FDA Clearance for AngioAnalytics, First OCT Angiography Metrics

Nexy Robotic Retinal Imaging System Receives FDA Clearance

Ocutrx Receives US Patent for Oculenz AR Glasses for Macular Degeneration

Allergan’s Bimatoprost SR Demonstrates Noninferiority to Timolol in Phase III Glaucoma Study

KKR to acquire Envision Healthcare, Including Amsurg ASC Business

Ophthalmologist Carmen Puliafito, MD, Seeks to Regain Medical License

Avedro Gains J Code for Photrexa Formulations in Preliminary CMS Decision

EyeGate Seeks to Study Ocular Bandage Gel in Punctate Epitheliopathy

Nicox, Ironwood to Collaborate on Novel Ophthalmic Treatments

US FDA Approves MDGH’s Moxidectin for Treatment of River Blindness

Bausch + Lomb Enrolls First Patient in Trial for enVista MX60EF Trifocal IOL

Cincinnati Eye Institute Partners with Private Equity Firm to Pursue National Expansion

Ophthotech Enters Gene Therapy Deals with University of Florida, University of Pennsylvania

Teva’s Launches Generic Version of Restasis in Canada

Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

Orasis Raises $13 Million in Series B Financing

Coming soon

2018 Glaucoma Device Report: A Global Market Analysis for 2017 to 2023